ArticleBMC infectious diseases2025
A comparative clinical features of COVID-19 in Non-elderly adult and elderly populations of Kermanshah province in Iran: a retrospective study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionCOVID-19, caused by the SARS-CoV-2, emerged as a lethal infectious disease with viral pneumonia-like symptoms, and was first identified in Wuhan, China, in December 2019. This study aimed to compare the epidemiological characteristics and clinical manifestations of COVID-19 between elderly and non-elderly adult populations in Kermanshah Province, Iran.
methodsThis retrospective study included 20,943 COVID-19 patients diagnosed between March 2020 and July 2021. Data were collected from the Medical Care Monitoring Center (MCMC) and comprised demographic information, comorbidities, clinical symptoms, hospitalization duration, and outcomes (discharge or mortality). Statistical analyses were performed using chi-square tests, Kaplan-Meier survival analysis, and multivariate Cox regression.
resultsOf the 20,943 patients, 7,174 (34.3%) were aged 65 years or older. Elderly patients exhibited a higher prevalence of comorbidities such as diabetes (11.5% vs. 6.5%), heart disease (11.7% vs. 3.6%), and COPD (1.8% vs. 0.7%) compared to younger adults (P < 0.001). Additionally, elderly patients had a significantly higher mortality rate (19.4% vs. 6.0%) and shorter median survival time (18 days vs. 36 days) (P < 0.001). Severe symptoms, including hypoxemia (SpO2 < 93%) and altered mental status, were also more common in the elderly.
conclusionThis study showed that elderly COVID-19 patients are at a higher risk of severe illness and mortality compared to younger adults. The presence of comorbidities and more severe clinical manifestations in this age group led to increased hospitalization duration and mortality. These findings underscore the importance of targeted clinical management and public health policies for the elderly population in the context of COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.